{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:17:15Z","timestamp":1791173835787,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,1,20]]},"DOI":"10.1200\/jco.2008.19.8853","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T02:43:27Z","timestamp":1229395407000},"page":"469-471","source":"Crossref","is-referenced-by-count":327,"title":["Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR\/ABL Mutants"],"prefix":"10.1200","volume":"27","author":[{"given":"Sara","family":"Redaelli","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S Gerardo Hospital, Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S Gerardo Hospital, Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rostagno","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S Gerardo Hospital, Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Magistroni","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S Gerardo Hospital, Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Perini","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S Gerardo Hospital, Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Marega","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S Gerardo Hospital, Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S Gerardo Hospital, Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Boschelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wyeth Pharmaceuticals, Pearl River, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103523"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00979-3"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093617"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70342-X"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"R12","unstructured":"Golas J, Arndt K, Etienne C, et al: SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63:375,2003-381,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.2930.2930"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.733.733"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-086801"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.7001"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-092056"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Quintas-Cardama A, Cortes J: Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk Res 2008","DOI":"10.1016\/j.leukres.2007.12.006"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035493"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.19.8853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:41:15Z","timestamp":1653522075000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.19.8853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,20]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,1,20]]}},"alternative-id":["10.1200\/JCO.2008.19.8853"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.19.8853","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,20]]}}}